Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

被引：2

作者：

Strati, Paolo ^{[1
]}

Champion, Rebecca ^{[2
]}

Coleman, Morton ^{[3
]}

Smith, Sonali M. ^{[4
]}

Venugopal, Parameswaran ^{[5
]}

Martin, Peter ^{[6
]}

Wood, Andrew ^{[7
]}

Miller, Kara ^{[8
]}

Christian, Beth ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Norton Canc Inst, Louisville, KY USA

[3] Weill Cornell Med, Clin Res Alliance, New York, NY USA

[4] Univ Chicago, Med Ctr, Chicago, IL USA

[5] Rush Univ, Med Ctr, Chicago, IL USA

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[7] AstraZeneca, Cambridge, England

[8] AstraZeneca, South San Francisco, CA USA

[9] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 06期

关键词：

B-cell lymphoma; Bruton tyrosine kinase; non-Hodgkin lymphoma; TYROSINE KINASE INHIBITOR; B-CELLS; IBRUTINIB; ACP-196;

D O I：

10.1111/bjh.19787

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.

引用

页码：2248 / 2253

页数：6

共 50 条

[21] Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study
Tilly, Herve
Morschhauser, Franck
Casasnovas, Olivier
Molina, Thierry Jo
Feugier, Pierre
Le Gouill, Steven
Haioun, Corinne
Tournilhac, Olivier
Bouabdallah, Reda
Gabarre, Jean
Lamy, Thierry
Cabecadas, Jose
Becker, Stephanie
Jardin, Fabrice
Mounier, Nicolas
Salles, Gilles
LANCET HAEMATOLOGY, 2018, 5 (09): : E403 - E410
[22] Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway
Haukaas, Fredrik Salvesen
Ohna, Audun
Krivasi, Tania
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (04) : 569 - 577
[23] Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
Park, Changhee
Lee, Ho Sup
Kang, Ka-Won
Lee, Won-Sik
Do, Young Rok
Kwak, Jae-Yong
Shin, Ho-Jin
Kim, Sung-Yong
Yi, Jun Ho
Lim, Sung-Nam
Lee, Jeong-Ok
Yang, Deok-Hwan
Jang, Hun
Choi, Byoungsan
Lim, Jiwoo
Sun, Choong Hyun
Byun, Ja Min
Yoon, Sung-Soo
Koh, Youngil
NATURE COMMUNICATIONS, 2024, 15 (01)
[24] ECONOMIC ANALYSIS OF RITUXIMAB In Combination with Cyclophosphamide, Vincristine and Prednisolone in the Treatment of Patients with Advanced Follicular Lymphoma in Portugal
Braga, Paula
Carvalho, Susana
Gomes, Marilia
Guerra, Lurdes
Lucio, Paulo
Marques, Herlander
Negreiro, Filipa
Pereira, Catarina
Silva, Catarina
Teixeira, Adriana
ACTA MEDICA PORTUGUESA, 2010, 23 (06): : 1025 - 1034
[25] The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study
Ramchandren, Radhakrishnan
Johnson, Peter
Ghosh, Nilanjan
Ruan, Jia
Ardeshna, Kirit M.
Johnson, Roderick
Verhoef, Gregor
Cunningham, David
de Vos, Sven
Kassam, Shireen
Fayad, Luis
Radford, John
Bailly, Sarah
Offner, Fritz
Morgan, David
Munoz, Javier
Ping, Jerry
Szafer-Glusman, Edith
Eckert, Karl
Neuenburg, Jutta K.
Goy, Andre
ECLINICALMEDICINE, 2023, 56
[26] An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
Andorsky, David J.
Kolibaba, Kathryn S.
Assouline, Sarit
Forero-Torres, Andres
Jones, Vicky
Klein, Leonard M.
Patel-Donnelly, Dipti
Smith, Mitchell
Ye, Wei
Shi, Wen
Yasenchak, Christopher A.
Sharman, Jeff P.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) : 215 - 222
[27] Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study
Chen, Tingting
Zeng, Chenggong
Wang, Juan
Sun, Feifei
Huang, Junting
Zhu, Jia
Lu, Suying
Liao, Ning
Zhang, Xiaohong
Chen, Zaisheng
Yuan, Xiuli
Yang, Zhen
Guo, Haixia
Yang, Liangchun
Wen, Chuan
Zhang, Wenlin
Li, Yang
Luo, Xuequn
Wu, Zelin
Yang, Lihua
Liu, Riyang
Zheng, Mincui
He, Xiangling
Sun, Xiaofei
Zhen, Zijun
CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 1252 - 1261
[28] Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies
Rule, Simon
Dreyling, Martin
Goy, Andre
Hess, Georg
Auer, Rebecca
Kahl, Brad
Cavazos, Nora
Liu, Black
Yang, Shiyi
Clow, Fong
Goldberg, Jenna D.
Beaupre, Darrin
Vermeulen, Jessica
Wildgust, Mark
Wang, Michael
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (03) : 430 - 438
[29] Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Czuczman, Myron S.
Fayad, Luis
Delwail, Vincent
Cartron, Guillaume
Jacobsen, Eric
Kuliczkowski, Kazimierz
Link, Brian K.
Pinter-Brown, Lauren
Radford, John
Hellmann, Andrzej
Gallop-Evans, Eve
DiRienzo, Christine G.
Goldstein, Nancy
Gupta, Ira
Jewell, Roxanne C.
Lin, Thomas S.
Lisby, Steen
Schultz, Martin
Russell, Charlotte A.
Hagenbeek, Anton
BLOOD, 2012, 119 (16) : 3698 - 3704
[30] Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group
Popovic, Stevan
Jovanovic, Darjana
Mihaljevic, Biljana
Andjelkovic, Nebojsa
Marjanovic, Goran
Marisavljevic, Dragomir
Vlaisavljevic, Nada
Popovic, Lazar
Salma, Svetlana
Agic, Danijela
Milosevic, Rajko
Smiljanic, Mihajlo
Sretenovic, Snezana
Djurdjevic, Predrag
Markovic, Olivera
Hajder, Jelena
Govedarovic, Nenad
JOURNAL OF BUON, 2017, 22 (02): : 487 - 494

← 1 2 3 4 5 →